The cell and gene therapy market is at a pivotal point, with a surge in approvals and a maturing pipeline. While oncology ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Researchers have used an experimental mRNA therapy to make old immune cells in mice behave as if they were young again, ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Cancer therapy and synthetic biology are converging around a shared problem that has long frustrated oncologists and ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN. IT REALLY ...

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

These factors prompted research into better and more permanent treatments for T1D. The most obvious solution: restore the natural repertoire of β cell islets. Although most recipients experienced ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. More than 70% of employers and health plans expect affordability of gene ...

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: raising the bar for his biotech’s investigational treatment. “I at least ...